Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kyntra Bio (KYNB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $213.8 million.

  • Kyntra Bio's Net Income towards Common Stockholders rose 58502.31% to $213.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.9 million, marking a year-over-year increase of 200347.42%. This contributed to the annual value of $105.5 million for FY2024, which is 17239.15% up from last year.
  • As of Q3 2025, Kyntra Bio's Net Income towards Common Stockholders stood at $213.8 million, which was up 58502.31% from $6.1 million recorded in Q2 2025.
  • Kyntra Bio's 5-year Net Income towards Common Stockholders high stood at $213.8 million for Q3 2025, and its period low was -$134.5 million during Q2 2021.
  • In the last 5 years, Kyntra Bio's Net Income towards Common Stockholders had a median value of -$64.3 million in 2023 and averaged -$29.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 28613.92% in 2022, then soared by 58502.31% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Net Income towards Common Stockholders stood at -$134.4 million in 2021, then soared by 50.56% to -$66.5 million in 2022, then plummeted by 39.86% to -$92.9 million in 2023, then skyrocketed by 128.67% to $26.6 million in 2024, then surged by 702.27% to $213.8 million in 2025.
  • Its Net Income towards Common Stockholders stands at $213.8 million for Q3 2025, versus $6.1 million for Q2 2025 and $21.4 million for Q1 2025.